Introduction:
Ventricular tachycardia (VT) commonly develops in patients with structural heart disease, especially those with myocardial scar, such as prior myocardial infarction. [1,2] Catheter ablation has been found to reduce incidence of VT storm, cardiovascular disease related hospitalization, and implanted cardioverter defibrillator (ICD) shocks when compared to medical therapy alone in patients with ischemic cardiomyopathy and structural heart disease. [3, 4]
Adverse events related to VT ablation include tamponade, stroke, and acute myocardial infarction. [5] chronic kidney disease (CKD) is associated with an increased incidence of adverse events in cardiovascular procedures such as percutaneous coronary interventions [6]. The aim of our study is to evaluate the impact of CKD on in-hospital mortality and clinical outcomes of VT ablation.